Anti-Human CD20 (Rituximab) PE, Clone: [10F381], Monoclonal

Artikelnummer: ABI-12-8027
Artikelname: Anti-Human CD20 (Rituximab) PE, Clone: [10F381], Monoclonal
Artikelnummer: ABI-12-8027
Hersteller Artikelnummer: 12-8027
Alternativnummer: ABI-12-8027-50UG
Hersteller: Abeomics
Wirt: Human
Kategorie: Sonstiges
Applikation: FACS
Immunogen: Human lymphoblastoid cell line SB.
Alternative Synonym: B1, S7, Bp35, CVID5, MS4A2, LEU-16, MS4A1, membrane spanning 4-domains A1
Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Rituximab. Clone 10F381 recognizes human CD20. This product is for research use only. CD20 is a 33-37 kD transmembrane-spanning phosphoprotein found on the surface of developing B-cells and various B-cell malignancies. CD20 is a popular target for mAb therapy because depleting developing B-cells generally does not cause permanent side effects (due to the fact that mature plasma cells and B-cell progenitors do not express CD20 and that there is limited expression of CD20 among other cell lineages). Rituximab is a chimeric monoclonal antibody that binds to CD20. The precise function of CD20 is still unknown. However, it is suspected to play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration, and allowing the activation of B cells. Rituximab is used to treat some autoimmune diseases and types of cancer such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis among others. The Fc portion of Rituximab mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen) and also induces apoptosis of CD20+ cells. This ultimately results in the elimination of B cells (including the cancerous ones) from the body, and thus allows a new population of healthy B cells to develop from lymphoid stem cells. Anti-Human CD20 (Rituximab) utilizes the same variable regions from the therapeutic antibody Rituximab making it ideal for research projects.
Klonalität: Monoclonal
Klon-Bezeichnung: [10F381]
Target-Kategorie: CD20
Antibody Type: Recombinant Antibody
Application Verdünnung: The suggested concentration for Rituximab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.